September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T magnetic resonance imaging (MRI) system at the 2017 annual meeting of the Radiological Society of North America (RSNA), Nov. 26-Dec. 1 in Chicago.

Telemis announced that the Groupement Radiologues Associés (GRA) in Bordeaux, France, chose Telemis's picture archiving and communication system (PACS) to renew its PACS system and implement exchange and sharing of medical images within their offices. GRA also chose EDL's RIS (radiology information system) Xplore Web and Cheops Technology's information technology (IT) infrastructure solutions.

What is the true meaning of “patient-centered care”? It’s the latest buzzword in healthcare, but how many of us fully understand the concept? Everything Rad explores the topic in depth in a special three-part blog series. Read part one today!

September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School of Medicine, recently discussed the rationale and design of the first clinical trial combining Theraclion’s Echotherapy with the checkpoint inhibitor pembrolizumab in women with metastatic breast cancer.

Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT) technology at the 2017 Radiological Society of North America (RSNA) annual meeting, Nov. 26-Dec. 1 in Chicago.

September 15, 2017 — Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Supria True64 computed tomography (CT) system.

September 15, 2017 — Philips highlighted its newest solution for nuclear cardiology, CardioMD IV, at the American Society of Nuclear Cardiology’s Annual Scientific Session, Sept. 14-17 in Kansas City, Mo. CardioMD IV leverages single photon emission computed tomography (SPECT) technology, advanced Astonish reconstruction and cardiac quantification software to deliver diagnostic confidence and improved workflow for cardiac imaging. 

Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The new approach utilizes a single molecule designed to bind two proteins with differing affinities in an effort to optimize specific tumor localization — prostate-specific membrane antigen (PSMA) and human serum albumin — thereby enhancing tumor localization for targeted alpha radionuclide therapy. The study is presented in the featured basic article of the September issue of The Journal of Nuclear Medicine.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now